Literature DB >> 2548535

Antibody-dependent cellular cytotoxicity is directed against both the gp120 and gp41 envelope proteins of HIV.

L A Evans1, G Thomson-Honnebier, K Steimer, E Paoletti, M E Perkus, H Hollander, J A Levy.   

Abstract

To define the target antigens for antibody-dependent cellular cytotoxicity (ADCC), assays were performed using affinity-purified human immunoglobulin (Ig) or polyclonal rabbit sera directed against specific proteins of HIV. ADCC was not found using affinity-purified anti-core (p25) human Ig or sera obtained from rabbits hyper-immunized with recombinant p25. However, when affinity-purified human Ig or rabbit antisera specific for the envelope glycoproteins, gp120 or gp41, were used in ADCC assays, killing of HIV-infected cells was observed. These results indicate that antibodies in the infected individual that mediate ADCC are directed against both the gp120 and gp41 HIV envelope proteins and not against the viral core protein.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2548535     DOI： 10.1097/00002030-198905000-00004

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  13 in total

1.  Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

Authors:  P S Polacino; V Stallard; J E Klaniecki; S Pennathur; D C Montefiori; A J Langlois; B A Richardson; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 2.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

3.  CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual.

Authors:  C E Mackewicz; H W Ortega; J A Levy
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

4.  Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

Authors:  J A Kovacs; M B Vasudevachari; M Easter; R T Davey; J Falloon; M A Polis; J A Metcalf; N Salzman; M Baseler; G E Smith
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

5.  Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

Authors:  P L Earl; W Sugiura; D C Montefiori; C C Broder; S A Lee; C Wild; J Lifson; B Moss
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

6.  Deficient antibody-dependent cellular cytotoxicity against human immunodeficiency virus (HIV)-expressing target cells in perinatal HIV infection.

Authors:  U Ziegner; D Campbell; K Weinhold; I Frank; R Rutstein; S E Starr
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

7.  Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines.

Authors:  Yanmin Wan; Lan Wu; Lianxing Liu; Jianqing Xu; Ying Liu; Yong Liu; Yiming Shao
Journal:  Vaccine       Date:  2007-02-26       Impact factor: 3.641

8.  Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.

Authors:  Samantha Townsley; Zeinab Mohamed; Wenjin Guo; Jennifer McKenna; Brad Cleveland; Celia LaBranche; David Beaumont; Xiaoying Shen; Nicole L Yates; Abraham Pinter; Georgia D Tomaras; Guido Ferrari; David C Montefiori; Shiu-Lok Hu
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

9.  Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.

Authors:  Ruth H Florese; Thorsten Demberg; Peng Xiao; LaRene Kuller; Kay Larsen; L Ebonita Summers; David Venzon; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

10.  Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization.

Authors:  Lianxing Liu; Yanling Hao; Zhenwu Luo; Yang Huang; Xintao Hu; Ying Liu; Yiming Shao
Journal:  Vaccine       Date:  2012-05-02       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.